• 17-SEP-2014

  • SOURCE: Novo Nordisk A/S

Novo Nordisk to publish New Data on IDegLira (EASD)

Novo Nordisk Logo

For medical media only

New IDegLira data from the phase 3a DUAL™ clinical programme will be presented at the 50th European Association for the Study of Diabetes (EASD) annual meeting and will be available for journalists through www.thenewsmarket.com on Friday 19 September at 11.31 CEST. IDegLira, the once-daily single injection combination of Tresiba® (insulin degludec) and Victoza® (liraglutide), has shown consistent results in improving glycaemic control in both insulin-naïve people with type 2 diabetes as well as those who are uncontrolled on basal insulin.

Available content will include:
•Soundbites by Prof Tina Vilsbøll, DUAL™ study Investigator, Gentofte Hospital, Denmark
•IDegLira EASD press release (Not intended for UK media)
•IDegLira EASD press release (For UK medical media only)
•DUAL™ I study backgrounder
•DUAL™ II study backgrounder
•Why combine basal insulin and a GLP-1 RA infographic (Not intended for UK media)
•Why combine basal insulin and a GLP-1 RA infographic (For UK medical media only)
•Diabetes in the UK backgrounder (For UK medical media only)


  • Client Relations